Drugs / Visnadine
Visnadine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03281655 | Dec 2016 → May 2017 | postmenopausal atrophic vaginitis | University of Messina | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visnadine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03281655 ↗ |
| Known as | Visnadin | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989444 ↗ |
| Known as | Visnadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989444 ↗ |
| Action | Inhibit | “visnadine, an active ingredient of the fruit of Ammi visnaga, showed powerful vasodilatory activity, due to the inhibitory effects on vascular smooth muscles mediated by Ca2+...” NCT03281655 ↗ |
| Modality | Small molecule | — CHEMBL3989444 ↗ |